GH secretagogueNot FDA-approvedBanned in sport (WADA)
Ipamorelin is a synthetic, selective growth-hormone secretagogue (a ghrelin-receptor agonist) studied for stimulating GH release with relatively few off-target hormonal effects.
Ipamorelin is a selective agonist of the ghrelin/GH-secretagogue receptor that stimulates growth-hormone release. It is valued in research for its selectivity — relatively little effect on cortisol or prolactin compared with older secretagogues — and is often paired with a GHRH analog like CJC-1295.
A synthetic research peptide, not an approved medication.
Mechanism:
Biologically plausible; long-term human outcome data is limited.
Early pharmacology supports GH release; long-term human outcome and safety data are limited.
| Evidence type | Status |
|---|---|
| Human pharmacology | Supports GH release with relative selectivity. |
| Long-term outcomes/safety | Limited. |
Studied around GH-axis modulation. Not an approved treatment.
Consider only with a licensed provider who can monitor labs and risk. Not a recommendation.
They act on complementary pathways (ghrelin receptor + GHRH receptor), which can amplify GH release in research settings.
No.
Yes — GH secretagogues are prohibited under WADA.
If you'd like help applying this information to your own health, schedule a consultation with the Bearing team.
Request a ConsultationReferences are provided for further reading. Bearing summarizes the literature conservatively and updates pages as evidence evolves.
Peptides: CJC-1295 · Sermorelin · Tools: Peptide Reconstitution Calculator